Factor XIII in bronchoalveolar lavage fluid from children with chronic bronchoalveolar inflammation

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1407-1413

  Katona, E ^a   Nagy, B ^a   Kappelmayer, J ^a   Baktai, G ^b   Kovacs L ^b   Marialigeti T ^c   Dezso, B ^a   Muszbek, László ^a,d  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Children's Hospital for Pulmonology 'Svábhegy'   (Hungary)

^c Department of Pediatrics   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Bronchoalveolar inflammation; Bronchoalveolar lavage fluid; Factor XIII

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 13B; D DIMER; FIBRIN; FIBRINOGEN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADOLESCENT; ARTICLE; BLOOD CLOTTING; BRONCHITIS; CAPILLARY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRIN DEPOSITION; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; LUNG ALVEOLITIS; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; MALE; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; BIOSYNTHESIS; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRONCHUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; INFANT; INFLAMMATION; LUNG ALVEOLUS; MACROPHAGE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; TIME;

ADOLESCENT; BRONCHI; BRONCHITIS; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARIES; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XIII; FACTOR XIII DEFICIENCY; FACTOR XIIIA; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; FLOW CYTOMETRY; HUMANS; INFANT; INFLAMMATION; MACROPHAGES; MALE; NEUTROPHILS; PULMONARY ALVEOLI; TIME FACTORS;

EID: 25144444423     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01353.x     Document Type: Article

References (45)

1. Idell S, Mazar AP, Bitterman P, Mohla S, Harabin AL. Fibrin turnover in lung inflammation and neoplasia. Am J Respir Crit Care Med 2001; 163: 578-84.
2. Bachofen M, Weibel ER. Structural alterations of lung parenchima in the adult respiratory distress syndrome. Clin Chest Med 1982; 3: 35-56.
3. Jackson LK. Idiopathic pulmonary fibrosis. Clin Chest Med 1982; 3: 579-92.
4. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury (review; 91 references). New Horiz 1994; 2: 566-74.
5. Hasday JD, Bachwich PR, Lynch JP III, Sitrin RG. Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis. Exp Lung Res 1988; 14: 261-78.
6. Gunther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, Morr H, Grimminger F, Walmrath D, Seeger W. Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83: 853-60.
7. Fujii M, Hayakawa H, Urano T, Sato A, Chida K, Nakamura H, Takada A. Relevance of tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99: 111-7.
8. Nakstad B, Lyberg T, Skjonsberg OH, Boye NP. Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57: 827-38.
9. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-62.
10. Muszbek L, Yee VC, Hevessy ZS. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94: 271-305.
11. Muszbek L, Adany R, Szegedi G, Polgar J, Kavai M. Factor XIII of blood coagulation in human monocytes. Thromb Res 1985; 37: 401-10.
12. Henriksson P, Becker S, Lynch G, McDonagh J. Identification of intracellular factor XIII in human monocytes and macrophages. J Clin Invest 1985; 76: 528-34.
13. Adany R, Belkin A, Vasilevskaya T, Muszbek L. Identification of blood coagulation factor XIII in human peritoneal macrophages. Eur J Cell Biol 1985; 38: 171-3.
14. Ádány R, Nemes Z, Muszbek L. Characterization of factor XIII containing macrophages in lymph nodes with Hodgkin's disease. Br J Cancer 1987; 55: 421-6.
15. Ádány R, Kiss A, Muszbek L. Factor XIII: a marker of mono- and megakaryocytopoesis. Br J Haematol 1987; 67: 167-72.
16. Kradin RL, Lynch GW, Kurnick JT, Erikson M, Colvin RB, McDonagh J. Factor XIII A is synthesized and expressed on the surface of U937 cells and alveolar macrophages. Blood 1987; 69: 778-85.
17. Muszbek L, Polgár J, Boda Z. Platelet factor XIII becomes active without the release of activation peptide during platelet activation. Thromb Haemost 1993; 69: 282-5.
18. Muszbek L, Haramura G, Polgár J. Transformation of cellular factor XIII into an active zymogen transglutaminase in thrombin-stimulated platelets. Thromb Haemost 1995; 74: 702-5.
19. Adany R, Szegedi A, Ablin RJ, Muszbek L. Fibrinolysis resistant fibrin deposits in lymph nodes with Hodgkin's disease. Thromb Haemost 1988; 60: 293-7.
20. Muszbek L, Ádány R. Intratumoral fibrin stabilization. In: Nigam SK, McBrian DCH, Slater TF, eds. Lipid Peroxidation and Cancer. Berlin: Springer Verlag, 1988: 339-49.
21. Katona E, Ajzner E, Toth K, Karpati L, Muszbek L. Enzyme linked immunosorbent assay for the determination of blood coagulation factor XIII A-subunit in plasma and cell lysates. J Immunol Meth 2001; 258: 127-35.
22. 2). Thromb Haemost 2000; 83: 268-73.
23. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis. Am Rev Respir Dis 1989; 140: 1527-37.
24. Nagy B, Katona E, Erdei J, Szekely E, Marialigeti T, Karmazsin L, Fachet J. Fibronectin in bronchoalveolar lavage fluid and plasma from children with chronic inflammation of lungs. Acta Paediatr Scand 1988; 77: 727-33.
25. Haugen TS, Nakstad B, Skjonsberg OH, Lyberg T. CD14 expression and binding of lipopolysaccharide to alveolar macrophages and monocytes. Inflammation 1998; 22: 521-32.
26. Perez-Arellano JL, Losa-Garcia JE, Orfao-Matos A, Gonzalez M, de la Cruz JL, Jimenez A, de Castro S. Comparison of two techniques (flow cytometry and alkaline immunophosphatase) in the evaluation of alveolar macrophage immunophenotype. Diagn Cytopathol 1993; 9: 259-65.
27. Polgár J, Hidasi V, Muszbek L. Non-proteolytic activation of cellular protransglutaminase (placenta macrophage factor XIII). Biochem J 1990; 267: 557-60.
28. Hirahara K, Shinbo K, Takahashi M, Matsuishi T. Suppressive effect of human blood coagulation factor XIII on the vascular permeability induced by anti-guinea pig endothelial cell antiserum in guinea pigs. Thromb Res 1993; 71: 139-48.
29. Noll T, Wozniak G, McCarson K, Hajimohammad A, Metzner HJ, Inserte J, Kummer W, Hehrlein FW, Piper HM. Effect of factor XIII on endothelial barrier function. J Exp Med 1999; 189: 1373-82.
30. Yorifuji H, Anderson K, Lynch GW, Van de Water L, McDonagh J. B protein of factor XIII: differentiation between free B and complexed B. Blood 1988; 72: 1645-50.
31. Kroll J. The subunit composition of factor XIII proteins in normal and factor XIII deficient plasma and serum analyzed by line immunoelectrophoresis. Clin Chim Acta 1989; 179: 279-84.
32. Fuchs-Buder T, de Moerloose P, Ricou B, Reber G, Vifian C, Nicod L, Romand JA, Suter PM. Time course of procoagulant activity and D-dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Crit Care Med 1966; 153: 163-7.
33. Muszbek L, Bereczky Z, Katona E. Blood coagulation factor XIII: Involvement in fibrinolysis and thrombosis. In: Arnout J, de Gaetano G, Hoylaerts M, Peerlinck K, Van Geet C, Verhaeghe R, eds. Thrombosis: Fundamental and Clinical Aspects. Leuven: Leuven University Press, 2003: 197-224.
34. 2- plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
35. Jansen JW, Haverkate F, Koopman J, Nieuwenhuis HK, Kluft C, Boschman TA. Influence of factor XIIIa activity on human whole blood clot lysis in vitro. Thromb Haemost 1987; 57: 171-5.
36. Jensen PH, Lorand L, Ebbesen P, Gliemann J. Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Eur J Biochem 1993; 214: 141-6.
37. 2-antiplasmin to fibrin(ogen). J Biol Chem 2000; 275: 24915-20.
38. Valnickova Z, Enghild JJ. Human procarboxipeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. J Biol Chem 1998; 273: 27220-4.
39. Mikus P, Urano T, Liljestrom P, Ny T. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur J Biochem 1993; 218: 1071-82.
40. Ritchie H, Robbie LA, Kinghorn S, Exley R, Booth NA. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. Thromb Haemost 1999; 81: 96-103.
41. Chapman HA, Yang XL, Sailor LZ, Sugarbaker DJ. Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury. J Immunol 1990; 145: 3398-405.
42. Ritchi H, Booth NA. Secretion of plasminogen activator inhibitor 2 by human peripheral blood monocytes occurs via an endoplasmic reticulum- golgi-independent pathway. Exp Cell Res 1998; 242: 439-50.
43. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
44. Moir E, Robbie LA, Bennett B, Booth NA. Polymorphonuclear leucocytes have two opposing roles in fibrinolysis. Thromb Haemost 2002; 87: 1006-10.
45. Bach-Gansmo ET, Gogal HC, Skjonsberg OH. Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test. Thromb Res 1998; 92: 125-34.